Beyond corticosteroids: Future prospects in the management of inflammation in COPD

European Respiratory Review

Volumn 20, Issue 121, 2011, Pages 175-182

  Roche, N ^a   Marthan, R ^b   Berger, P ^b   Chambellan, A ^c   Chanez, P ^d   Aguilaniu, B ^e   Brillet, P Y ^f   Burgel, P R ^a   Chaouat, A ^g   Devillier, P ^h   Escamilla, R ⁱ   Louis, R ^j   Mal, H ^k   Muir, J F ^l   Perez T ^m   Similowski, T ^a   Wallaert, B ^m   Aubier, M ^k  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e HYLAB   (France)

^f UNIVERSITÉ PARIS 13   (France)

^g CHU NANCY BRABOIS   (France)

^h LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

ⁱ SERVICE DE PNEUMOLOGIE   (France)

^j UNIVERSITY OF LIÈGE   (Belgium)

^k BICHAT HOSPITAL   (France)

^l Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^m LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Chronic obstructive pulmonary disease; Inflammation; Mucus hypersecretion; Phosphodiesterase 4 inhibitors; Repair; Treatment

Indexed keywords

ACETYLCYSTEINE; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; ERYTHROMYCIN; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROSIGLITAZONE; SALMETEROL; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; COMMON COLD; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; HEARING IMPAIRMENT; HEART DISEASE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPIC VARIATION; PNEUMONIA; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; HUMANS; LUNG; PHENOTYPE; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 80052606325     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00004211     Document Type: Review

References (80)

1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
2. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
4. Aubier M, Marthan R, Berger P, et al. BPCO et inflammation: mise au point d'un group d'experts. Les mécanismes de l'inflammation et du remodelage [COPD and inflammation: statement from a French expert group: inflammation and remodelling mechanisms]. Rev Mal Respir 2010; 27: 1254-1266.
5. Pérez T, Mal H, Aguilaniu B, et al. BPCO et inflammation: mise au point d'un group d'experts. Les phénotypes en lien avec l'inflammation [COPD and inflammation: statement from a French expert group. Phenotypes related to inflammation]. Rev Mal Respir 2011; 28: 192-215.
6. Roche N, Devillier P, Aguilaniu B, et al. BPCO et inflammation: mise au point d'un group d'experts. Comment traiter l'inflammation? [COPD and inflammation: statement from a French expert group. How to treat inflammation?]. Rev Mal Respir 2011; 28: 427-442.
7. Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147: 301-306.
8. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
9. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
10. Freeman CM, Martinez FJ, Han MK, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 1179-1188.
11. Brusselle GG, Demoor T, Bracke KR, et al. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009; 34: 219-230.
12. van der Strate BW, Postma DS, Brandsma CA, et al. Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med 2006; 173: 751-758.
13. Barnes PJ. Emerging Pharmacotherapies for COPD. Chest 2008; 134: 1278-1286.
14. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 50-60.
15. Stevenson CS, Koch LG, Britton SL. Aerobic capacity, oxidant stress, and chronic obstructive pulmonary disease - a new take on an old hypothesis. Pharmacol Ther 2006; 110: 71-82.
16. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180.
17. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905-17.
18. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.
19. Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
20. Di Stefano A, Turato G, Maestrelli P, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med 1996; 153: 629-632.
21. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8 T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
22. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473.
23. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102-1108.
24. O'Donnell RA, Peebles C, Ward JA, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837-842.
25. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105-110.
26. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
27. Bhowmik A, Seemungal TAR, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120.
28. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-1623.
29. Baghai-Ravary R, Quint JK, Goldring JJ, et al. Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med 2009; 103: 216-223.
30. Agustý́ AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
31. Growcott EJ, Spink KG, Ren X, et al. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 2006; 7: 9.
32. Izikki M, Raffestin B, Klar J, et al. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotalineinduced pulmonary hypertension in rats. J Pharmacol Exp Ther 2009; 330: 54-62.
33. Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529-1534.
34. Keatings V, Jatakanon A, Worsdell Y, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 548.
35. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583-585.
36. Barnes NC, Qiu YS, Pavord ID, et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
37. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
38. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
39. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
40. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
41. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.
42. Worth H, Förster K, Eriksson G, et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med 2010; 104: 1450-1459.
43. Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008; 31: 927-933.
44. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010; 363: 2233-2247.
45. Chapron-Fouché J, Burgel PR. Mucolytics and other therapeutic agents targeting mucociliary clearance. In: EMC Pneumologie, ed. Paris, Elsevier Masson SAS, 2009; 6-000-P-010.
46. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 2: CD001287.
47. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560.
48. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569.
49. Garbacki N, Di Valentin E, Piette J, et al. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm Pharmacol Ther 2009; 22: 267-278.
50. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599-2608.
51. Djekic UV, Gaggar A, Weathington NM. Attacking the multitiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther 2009; 121: 132-146.
52. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
53. Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest 2008; 134: 606-612.
54. Jin T, Xu X, Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine 2008; 44: 1-8.
55. Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Inflamm Allergy 2005; 4: 313-317.
56. Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009; 121: 55-68.
57. Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006; 27: 546-553.
58. Yamagata T, Ichinose M. Agents against cytokine synthesis or receptors. Eur J Pharmacol 2006; 533: 289-301.
59. Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov Today 2007; 12: 479-486.
60. Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695.
61. Ford PA, Durham AL, Russell REK, et al. Treatment effects of lowdose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010; 137: 1338-1344.
62. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081-1087.
63. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 976-982.
64. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009; 374: 685-694.
65. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
66. López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008; 8: 286-291.
67. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
68. Albert RK, Bailey WC, Casaburi R, et al. Chronic azithromycin decreases the frequency of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2011; 183: A6416.
69. Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009; 85: 414-421.
70. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
71. Janda S, Park K, Fitzgerald M, et al. Statins in COPD. A systematic review. Chest 2009; 136: 734-743.
72. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence form a retrospective cohort study. Int J Clin Pract 2008; 62: 1373-1378.
73. Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality of COPD. Eur Respir J 2007; 29: 279-283.
74. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
75. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
76. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-747.
77. Lee TM, Lin MS, Chang NC. Usefulnes of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008; 101: 530-535.
78. Becker J, Delayre-Orthez C, Frossard N, et al. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006; 20: 429-447.
79. Spears M, McSharry C, Thomson NC. Peroxisome proliferatoractivated receptors-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006; 36: 1494-1504.
80. Birrell MA, Patel HJ, McCluskie K, et al. PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 2004; 24: 18-23.